RT Journal Article
SR Electronic
T1 All-cause mortality in an Idiopathic Pulmonary Fibrosis (IPF) cohort: retrospective analysis with cardiac QRISK-2
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3747
DO 10.1183/13993003.congress-2021.PA3747
VO 58
IS suppl 65
A1 Matthew Watson
A1 Thomas McLellan
A1 Muhunthan Thillai
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA3747.abstract
AB Background: Patients with IPF live longer with anti-fibrotic therapy but have high cardiovascular risk. This may increase mortality independent of the severity of their lung disease.The QRISK-2 score is validated in the UK. Using demographic (age, smoking history, ethnicity) and personal risk-factors (presence of hypercholesterolaemia/hypertension/renal/diabetic disease) it predicts the risk of a primary cardiovascular event within 10 years. A score of ≥10% indicates need for primary prevention and ≥20% is high risk.Aim: Assess the relationship between QRISK-2, IPF severity (TLCO, FVC and GAP-score) at diagnosis and all-cause mortality in IPF patients from a single UK-centre.Methods: Data for the study was taken from patient records. Individuals were followed-up until death or a cardiovascular event.Results: Mean follow up for 248 patients (table 1) was 3.1 years. 141 patients died. There were 11 cardiovascular events.Mean QRISK score was 27.0% (SD 12.3). 70% (n=172) had a QRISK-2 >20%. There was no survival difference when patients were stratified by diagnosis TLCO, FVC or GAP-stage. Patients with a QRISK<20% at diagnosis survived longer than those with a QRISK>20% (fig 1). Conclusion: Multimorbidity in IPF patients affects mortality. The QRISK-2 may be a useful marker of this. TLCO and FVC at diagnosis did not predict mortality. The effect of anti-fibrotic therapy may have been contributory.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3747.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).